N1-(4-丁基-3-羟苯基)乙酰胺 | 28583-62-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N1-(4-丁基-3-羟苯基)乙酰胺
• 英文名称: N-(4-butyryl-3-hydroxyphenyl)acetamide
• 英文别名: acetic acid-(3-hydroxy-4-butyryl-anilide)；Essigsaeure-(3-hydroxy-4-butyryl-anilid)；N-[3-hydroxy-4-(1-oxobutyl)phenyl]acetamide；4'-Butyryl-3'-hydroxyacetanilide；N-(4-butanoyl-3-hydroxyphenyl)acetamide
• CAS: 28583-62-2
• 化学式: C₁₂H₁₅NO₃
• mdl: MFCD00276573
• 分子量: 221.256
• InChiKey: RSBIKRQPSYDRFZ-UHFFFAOYSA-N

物化性质

• 熔点：
  85 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2924299090

SDS

Name:	N1-(4-butyryl-3-hydroxyphenyl)acetamide tech Material Safety Data Sheet
Synonym:	4-(Acetamido)-2-hydroxybutyrophenon
CAS:	28583-62-2

Section 1 - Chemical Product MSDS Name:N1-(4-butyryl-3-hydroxyphenyl)acetamide tech Material Safety Data Sheet
Synonym:4-(Acetamido)-2-hydroxybutyrophenon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
28583-62-2	N1-(4-Butyryl-3-hydroxyphenyl)acetamid		249-092-6

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 28583-62-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 0

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 28583-62-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(4-Butyryl-3-hydroxyphenyl)acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 28583-62-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 28583-62-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 28583-62-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N1-(4-丁基-3-羟苯基)乙酰胺 在 2-双环己基膦-2',6'-二甲氧基联苯 、 sodium tetrahydroborate 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 碘 、 sodium hydride 、 溶剂黄146 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 75.0 ℃ 、413.7 kPa 条件下， 反应 34.25h， 生成 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one
  参考文献：
  名称：

  4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

  摘要：

  提供了4(1H)-喹啉酮衍生物，能有效抑制或消除疟原虫生命周期中至少一个阶段的生存能力，并且显示出减少目标寄生虫对化合物产生抗药性的倾向。具体来说，这些化合物可以是苯氧乙氧基喹啉酮的衍生物，包括但不限于7-(2-苯氧乙氧基)喹啉衍生物。这些化合物可以单独或与至少另一种衍生物化合物或其他抗疟疾化合物一起，向动物或人类受试者施用。治疗组合物可以配制成减少受试者体内疟原虫感染程度的程度，或者在寄生虫接触受试者之前施用，以减少疟原虫感染的可能性。治疗组合物可以配制成提供有效的单剂量抗疟疾化合物或多剂量，以在一段时间内施用。

  公开号：

  US20130123258A1
• 作为产物：
  描述：

  N-(3-羟基苯基)乙酰胺 在 吡啶 、 aluminum (III) chloride 作用下， 反应 0.5h， 生成 N1-(4-丁基-3-羟苯基)乙酰胺
  参考文献：
  名称：

  7-(2-苯氧基乙氧基)-4(1H)-喹诺酮类的合成、抗疟活性及构效关系

  摘要：

  ICI 56,780 ( 5 ) 在啮齿动物疟疾模型中显示出因果预防和血液分裂活性（ED 50 = 0.05 mg/kg），但在感染伯氏疟原虫的小鼠中迅速获得了寄生虫学抗性。在此，我们描述了针对多药耐药恶性疟原虫的 EC 50低至 0.15 nM的5类似物的合成。通过在 7-(2-phenoxyethoxy)-4(1 H )-quinolone 核心的 3 位引入邻位取代的芳基部分，实现了对 atovaquone 的低交叉阻力指数 (RI) 的最佳活性。

  DOI：

  10.1021/jm200718m

文献信息

• Structure and anticoccidial activity among some 4-hydroxyquinolinecarboxylates
  作者：Renat H. Mizzoni

  DOI：10.1021/jm00299a019

  日期：1970.9
• Julia; Baillarge, Bulletin de la Societe Chimique de France, 1952, p. 639
  作者：Julia、Baillarge

  DOI：——

  日期：——
• Antitumor effects of guanosine-analog phosphonates identified by molecular modelling
  作者：Anja Schwanke、Caterina Murruzzu、Barbara Zdrazil、Ralf Zuhse、Maja Natek、Monika Höltje、Hans Christian Korting、Hans-Ulrich Reissig、Hans-Dieter Höltje、Monika Schäfer-Korting

  DOI：10.1016/j.ijpharm.2010.06.036

  日期：2010.9

  Aiming to address new drug targets, molecular modelling is gaining increasing importance although the prediction capability of the in silico method is still under debate. For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase alpha (pol alpha) are developed by docking nucleoside phosphonate diphosphates into the active site of pol alpha. The most promising prodrugs OxBu and OxHex were then prepared by total synthesis and tested in the squamous cancer cell line SCC25. OxBu and OxHex proved cytotoxic and antiproliferative in the nanomolar concentration range and thus exceeded activity of aphidicolin, the relevant model compound, and 5-fluorouracil, the current standard for the therapy of actinic keratosis. Interestingly, the cytotoxicity in normal human keratinocytes with OxHex was clearly less pronounced and even not detectable with OxBu. Moreover, cytotoxicity of OxBu in particular with the colorectal carcinoma cell line HT29 even surmounted cytotoxicity in SCC25, and other tumor cell lines were influenced, too, by both agents. Taken together, OxBu and OxHex may offer a new approach to cancer therapy, given the agents are sufficiently well tolerated in vivo which is to be suspected beside their chemical structure. (C) 2010 Elsevier B.V. All rights reserved.
• Julia; Tchernoff, Bulletin de la Societe Chimique de France, 1952, p. 779,781
  作者：Julia、Tchernoff

  DOI：——

  日期：——
• POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS
  申请人：Schaefer-Korting Monika

  公开号：US20110182973A1

  公开（公告）日：2011-07-28

  The invention relates to polymerase inhibitors, particularly polymerase alpha inhibitors, and the use thereof in the treatment of cell growth disorders, particularly tumor disorders, preferably actinic keratoses, basal cell carcinomas, and/or spinocellular carcinomas.